Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Botensilimab, botensilimab
Botensilimab+ Balstilimab · 1 trial · 1 indication
12-Month PFS is defined as the proportion of patients who remain alive and progression-free at 12 months from the first dose of investigational drug, where tumor progression is documented per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) and modified Response Evaluation Criteria in Solid Tumors version 1.1 for immune-based therapeutics (iRECIST) as assessed by investigator.
| Arm | Type | Description |
|---|---|---|
| Botensilimab + Balstilimab | EXPERIMENTAL | botensilimab 75 mg IV every 6 weeks (up to 4 doses) + balstilimab 240 mg IV every 2 weeks |
| Name | Type | Description |
|---|---|---|
| Botensilimab + Balstilimab | DRUG | Botensilimab is a fragment crystallizable (Fc)-engineered human immunoglobulin G1 (IgG1) monoclonal antibody that targets cytotoxic T lymphocyte-associated protein 4 (CTLA-4). Balstilimab is a human monoclonal antibody that targets programmed cell death protein 1 (PD-1). |
Inclusion Criteria: 1. Histologically and IHC confirmed diagnosis of metastatic NSCLC which has not received any prior anticancer medicinal therapy for metastatic disease. 2. Negative for actionable EGFR mutations and ALK rearrangements. 3. Patients with recurrence after prior neoadjuvant or adjuva...
Top 20 of 84 competitors
Botensilimab is an investigational antibody being studied for the treatment of several cancers, including non-small cell lung cancer, metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, early rectal cancer, and advanced cancer. It is being developed by Agenus Inc. and is currently in Phase 1 clinical trials.
Botensilimab is a monoclonal antibody, indicated by its -mab suffix. As an antibody, it is designed to bind to specific targets involved in cancer. However, the specific molecular target has not been disclosed in the available information.
Botensilimab is being developed by Agenus Inc., a biopharmaceutical company. Agenus is publicly traded under the ticker symbol AGEN. The company is conducting clinical trials to evaluate Botensilimab for various oncology indications.
Botensilimab is currently in Phase 1 clinical development. It has received Fast Track designation from the FDA. Botensilimab is investigational and has not been approved by the FDA for any indication.
Botensilimab is being studied in several clinical trials, including NCT05529316 for advanced melanoma, NCT05608044 for metastatic colorectal cancer, NCT06076837 for metastatic pancreatic cancer, and NCT06268015 for colorectal cancer. These trials are in Phase 1 or Phase 2 and are active but not recruiting.
Botensilimab is sometimes studied in combination with balstilimab, another investigational antibody. The combination is referred to as Botensilimab plus Balstilimab. Clinical trials such as NCT05608044 and NCT06268015 are evaluating this combination for colorectal cancer.